1-4 of 4
Laura Esserman
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Abstract A50: Circulating tumor DNA (ctDNA) and magnetic resonance imaging (MRI) for monitoring and predicting response to neoadjuvant therapy (NAT) in high-risk early breast cancer patients in the I-SPY 2 TRIAL

Mark Jesus M. Magbanua, Wen Li, Denise M. Wolf, Christina Yau, Gillian L. Hirst, Lamorna Brown-Swigart, A. Jo Chien, Amy L. Delson, Jessica Gibbs, Alexey Aleshin, Bernhard Zimmerman, I-SPY 2 Consortium, Laura Esserman, Nola Hylton, Laura van 't Veer
Journal: Clinical Cancer Research
Clin Cancer Res (2020) 26 (11_Supplement): A50.
https://doi.org/10.1158/1557-3265.LiqBiop20-A50
Published: 01 June 2020
View article titled, Abstract A50: Circulating tumor DNA (ctDNA) and magnetic resonance imaging (MRI) for monitoring and predicting response to neoadjuvant therapy (NAT) in high-risk early breast cancer patients in the I-SPY 2 TRIAL
Journal Articles

Synchronous Detection of Circulating Tumor Cells in Blood and Disseminated Tumor Cells in Bone Marrow Predicts Adverse Outcome in Early Breast Cancer

Mark Jesus M. Magbanua, Christina Yau, Denise M. Wolf, Jin Sun Lee, Aheli Chattopadhyay, Janet H. Scott, Erin Bowlby-Yoder, E. Shelley Hwang, Michael Alvarado, Cheryl A. Ewing, Amy L. Delson, Laura J. van't Veer, Laura Esserman, John W. Park
Journal: Clinical Cancer Research
Clin Cancer Res (2019) 25 (17): 5388–5397.
https://doi.org/10.1158/1078-0432.CCR-18-3888
Published: 03 September 2019
View article titled, Synchronous Detection of Circulating Tumor Cells in Blood and Disseminated Tumor Cells in Bone Marrow Predicts Adverse Outcome in Early Breast Cancer
Open the PDF for Synchronous Detection of Circulating Tumor Cells in Blood and Disseminated Tumor Cells in Bone Marrow Predicts Adverse Outcome in Early Breast Cancer in another window
Includes: Supplementary data
Journal Articles

Developing Safety Criteria for Introducing New Agents into Neoadjuvant Trials

Angela DeMichele, Donald A. Berry, JoAnne Zujewski, Sally Hunsberger, Larry Rubinstein, Joseph E. Tomaszewski, Gary Kelloff, Jane Perlmutter, Meredith Buxton, Julia Lyandres, Kathy S. Albain, Chris Benz, A. Jo Chien, Paul Haluska, Brian Leyland-Jones, Minetta C. Liu, Pamela Munster, Olufunmilayo Olopade, John W. Park, Barbara A. Parker, Lajos Pusztai, Debu Tripathy, Hope Rugo, Douglas Yee, Laura Esserman
Journal: Clinical Cancer Research
Clin Cancer Res (2013) 19 (11): 2817–2823.
https://doi.org/10.1158/1078-0432.CCR-12-2620
Published: 30 May 2013
View article titled, Developing Safety Criteria for Introducing New Agents into Neoadjuvant Trials
Open the PDF for Developing Safety Criteria for Introducing New Agents into Neoadjuvant Trials in another window
Journal Articles

Molecular Analysis of HER2 Signaling in Human Breast Cancer by Functional Protein Pathway Activation Mapping

Julia D. Wulfkuhle, Daniela Berg, Claudia Wolff, Rupert Langer, Kai Tran, Julie Illi, Virginia Espina, Mariaelena Pierobon, Jianghong Deng, Angela DeMichele, Axel Walch, Holger Bronger, Ingrid Becker, Christine Waldhör, Heinz Höfler, Laura Esserman, on behalf of the I-SPY 1 TRIAL Investigators, Lance A. Liotta, Karl-Friedrich Becker, Emanuel F. Petricoin, III
Journal: Clinical Cancer Research
Clin Cancer Res (2012) 18 (23): 6426–6435.
https://doi.org/10.1158/1078-0432.CCR-12-0452
Published: 29 November 2012
View article titled, Molecular Analysis of HER2 Signaling in Human Breast Cancer by Functional Protein Pathway Activation Mapping
Open the PDF for Molecular Analysis of HER2 Signaling in Human Breast Cancer by Functional Protein Pathway Activation Mapping in another window
Includes: Supplementary data